Skye Bioscience, Inc. (SKYE)
USD 1.4
(-2.1%)
USD 1.4
(-2.1%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -5.72 Million USD | -938.24% |
| 2022 | 682.54 Thousand USD | 109.97% |
| 2021 | -6.84 Million USD | -604.71% |
| 2020 | -971.6 Thousand USD | 32.66% |
| 2019 | -1.44 Million USD | -193.03% |
| 2018 | -492.41 Thousand USD | -1873.2% |
| 2017 | -24.95 Thousand USD | 61.5% |
| 2016 | -64.82 Thousand USD | 97.99% |
| 2015 | -3.22 Million USD | -1453.66% |
| 2014 | -207.33 Thousand USD | -4090.18% |
| 2013 | -4948.00 USD | 81.26% |
| 2012 | -26.4 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -69.05 Million USD | 12.04% |
| 2024 Q1 | -78.5 Million USD | -1272.17% |
| 2023 FY | -5.72 Million USD | -938.24% |
| 2023 Q4 | -5.72 Million USD | -717.46% |
| 2023 Q2 | -188.78 Thousand USD | 92.23% |
| 2023 Q1 | -2.42 Million USD | -455.84% |
| 2023 Q3 | -699.89 Thousand USD | -270.73% |
| 2022 Q4 | 682.54 Thousand USD | -68.56% |
| 2022 Q2 | -396.25 Thousand USD | 88.75% |
| 2022 Q1 | -3.52 Million USD | 48.57% |
| 2022 FY | 682.54 Thousand USD | 109.97% |
| 2022 Q3 | 2.17 Million USD | 647.93% |
| 2021 FY | -6.84 Million USD | -604.71% |
| 2021 Q3 | -9.1 Million USD | -158.86% |
| 2021 Q1 | -3.51 Million USD | -261.58% |
| 2021 Q2 | -3.51 Million USD | -0.12% |
| 2021 Q4 | -6.84 Million USD | 24.8% |
| 2020 FY | -971.6 Thousand USD | 32.66% |
| 2020 Q4 | -971.6 Thousand USD | 66.12% |
| 2020 Q3 | -2.86 Million USD | -357.09% |
| 2020 Q2 | 1.11 Million USD | 2520.88% |
| 2020 Q1 | -46.08 Thousand USD | 96.81% |
| 2019 Q3 | 1.97 Million USD | 571.93% |
| 2019 Q1 | -1.49 Million USD | -204.36% |
| 2019 FY | -1.44 Million USD | -193.03% |
| 2019 Q2 | 294.21 Thousand USD | 119.63% |
| 2019 Q4 | -1.44 Million USD | -172.99% |
| 2018 Q4 | -492.41 Thousand USD | 53.48% |
| 2018 FY | -492.41 Thousand USD | -1873.2% |
| 2018 Q3 | -1.05 Million USD | 43.54% |
| 2018 Q2 | -1.87 Million USD | 36.35% |
| 2018 Q1 | -2.94 Million USD | -11702.49% |
| 2017 Q4 | -24.95 Thousand USD | 40.55% |
| 2017 Q1 | -380.27 Thousand USD | -486.66% |
| 2017 Q2 | -108.85 Thousand USD | 71.37% |
| 2017 Q3 | -41.97 Thousand USD | 61.44% |
| 2017 FY | -24.95 Thousand USD | 61.5% |
| 2016 Q4 | -64.82 Thousand USD | 79.74% |
| 2016 FY | -64.82 Thousand USD | 97.99% |
| 2016 Q1 | -2.06 Million USD | 36.0% |
| 2016 Q2 | -831.65 Thousand USD | 59.66% |
| 2016 Q3 | -319.93 Thousand USD | 61.53% |
| 2015 Q2 | -601.26 Thousand USD | -240.27% |
| 2015 Q4 | -3.22 Million USD | 25.83% |
| 2015 Q3 | -4.34 Million USD | -622.26% |
| 2015 Q1 | -176.7 Thousand USD | 14.77% |
| 2015 FY | -3.22 Million USD | -1453.66% |
| 2014 Q3 | -1.02 Million USD | -2587.92% |
| 2014 Q4 | -207.33 Thousand USD | 79.77% |
| 2014 Q1 | -14.59 Thousand USD | -168.92% |
| 2014 FY | -207.33 Thousand USD | -4090.18% |
| 2014 Q2 | 41.2 Thousand USD | 382.25% |
| 2013 Q2 | 15.37 Thousand USD | -43.67% |
| 2013 Q4 | -5428.00 USD | -9.7% |
| 2013 FY | -4948.00 USD | 81.26% |
| 2013 Q3 | -4948.00 USD | -132.19% |
| 2013 Q1 | 27.28 Thousand USD | 0.0% |
| 2012 Q3 | -26.4 Thousand USD | 0.0% |
| 2012 FY | -26.4 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -436647.252% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 201.293% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 113.37% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -2192.04% |
| Rebus Holdings, Inc. | 305 Thousand USD | 1975.865% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 9.249% |
| Qrons Inc. | 351.42 Thousand USD | 1728.045% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1019.299% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 113.173% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -27935.03% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 136.296% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 238.935% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 1523.766% |
| SQZ Biotechnologies Company | -36.23 Million USD | 84.212% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 355.165% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 717.07% |
| Mesoblast Limited | 55.85 Million USD | 110.243% |
| Marizyme, Inc. | 18.56 Million USD | 130.811% |
| Genus plc | 190.6 Million USD | 103.002% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 355.895% |
| Pharming Group N.V. | 109.8 Million USD | 105.211% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 765.091% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 571.328% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 941.381% |
| ContraFect Corporation | -6.02 Million USD | 5.055% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 4349.429% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 595.174% |
| IMV Inc. | 7.67 Million USD | 174.589% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 203.989% |
| MultiCell Technologies, Inc. | 90.04 USD | 6354374.767% |
| ONE Bio Corp. | 9.04 Million USD | 163.289% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -679.504% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 144.194% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 518.239% |
| Q BioMed Inc. | 4.06 Million USD | 240.921% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 118.725% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 667.758% |
| Biomind Labs Inc. | 711.4 Thousand USD | 904.241% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 109.45% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 386.156% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 144.675% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 1690.556% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 4192.436% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 28898.455% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 359.829% |
| GB Sciences, Inc. | 1.74 Million USD | 427.439% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -3013.037% |
| HST Global, Inc. | 96.79 Thousand USD | 6010.953% |
| CSL Limited | 10.52 Billion USD | 100.054% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 2874.451% |
| Halberd Corporation | 144.72 Thousand USD | 4053.392% |
| Enzolytics Inc. | 981.65 Thousand USD | 682.83% |
| Agentix Corp. | 37.63 Thousand USD | 15303.925% |
| Resverlogix Corp. | 6.45 Million USD | 188.69% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -750.02% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.718% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 87.83% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 180.914% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 311.229% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 35.278% |
| AVAX Technologies, Inc. | -5.9 Million USD | 3.08% |
| Zenith Capital Corp. | 10.06 Thousand USD | 56950.05% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.461% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 2954.529% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 339.787% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 3577.858% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -31133.699% |
| Kadimastem Ltd | -253.1 Thousand USD | -2160.507% |
| Helix BioMedix, Inc. | -2.57 Million USD | -122.619% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 128.218% |
| BioStem Technologies, Inc. | 4.47 Million USD | 227.938% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 2942.87% |
| LadRx Corporation | -2.03 Million USD | -180.947% |
| Cell Source, Inc. | 9.23 Million USD | 161.974% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1000.769% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1000.769% |
| NovAccess Global Inc. | 2.17 Million USD | 362.634% |
| Affymax, Inc. | -5.59 Million USD | -2.222% |
| Itoco Inc. | 228.3 Thousand USD | 2606.029% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 4307.244% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 215.42% |
| Mobile Lads Corp. | 484.23 Thousand USD | 1281.539% |
| CytoDyn Inc. | 20.26 Million USD | 128.237% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -884195.054% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -61630.461% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 174.246% |
| SYBLEU INC | 473.71 Thousand USD | 1307.773% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 228.368% |
| International Stem Cell Corporation | 2.59 Million USD | 320.903% |
| Bioxytran, Inc. | 1.89 Million USD | 401.298% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 9266.983% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 362.341% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 266.61% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 166.893% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 840.53% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -357.711% |
| Neutra Corp. | 52.18 Thousand USD | 11063.246% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -129.867% |
| PureTech Health plc | -167.19 Million USD | 96.578% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -2236.138% |
| IXICO plc | -4.44 Million USD | -28.727% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 143.282% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 110.431% |
| CSL Limited | 10.52 Billion USD | 100.054% |
| Cellectis S.A. | -43.81 Million USD | 86.943% |